Abbott Laboratories (ABT)

70.23
0.72 1.01
NYSE : Health Technology
Prev Close 70.95
Open 70.30
Day Low/High 69.17 / 70.69
52 Wk Low/High 53.61 / 74.15
Volume 10.69M
Avg Volume 5.48M
Exchange NYSE
Shares Outstanding 1.75B
Market Cap 120.52B
EPS 0.30
P/E Ratio 149.35
Div & Yield 1.12 (1.59%)

Latest News

Jim's Daily Rundown

Jim discusses Abbott Labs, Amgen, FANG, and the cannabis stocks, and provides his thoughts into today's release of the Fed minutes.

Abbott Labs Reports In-Line Third-Quarter Results

Company achieved solid growth in the face of currency challenges and we would be a buyer on this weakness.

Abbott Laboratories Posts Solid Q3 Earnings, Trims Full-Year Forecast

Abbott Laboratories Posts Solid Q3 Earnings, Trims Full-Year Forecast

Abbott Laboratories posted third quarter earnings that were largely in-line with analysts' forecasts, but trimmed the upper end of its full-year profit outlook as international sales were hit by a stronger U.S. dollar.

Netflix, IBM, Legal Pot in Canada, Mega Millions - 5 Things You Must Know

Netflix, IBM, Legal Pot in Canada, Mega Millions - 5 Things You Must Know

U.S. stock futures point lower on Wednesday, following the biggest single-day surge on Wall Street in more than six months; Netflix soars after third-quarter subscriber growth trounces expectations; IBM slumps as revenue at the tech giant slows; cannabis is now legal in Canada; the Mega Million jackpot climbs to $868 million.

Why Netflix Is a Good Name to Short on This Earnings Report: Market Recon

Why Netflix Is a Good Name to Short on This Earnings Report: Market Recon

I am unimpressed by the latest earnings report. Despite good subscriber growth, fundamentals look weak.

Abbott Reports Third-Quarter 2018 Results

Abbott Reports Third-Quarter 2018 Results

- Third-quarter reported sales growth of 12.1 percent; organic sales growth of 7.8 percent

Earnings Primer for the Week

UnitedHealth Group, Johnson and Johnson, Goldman Sachs, Abbott Laboratories, Danaher and Textron are just some of the companies reporting earnings this week.

Sell Abbott Laboratories Down to a 'Sleeping Position'

Sell Abbott Laboratories Down to a 'Sleeping Position'

While Abbott's charts are not screaming sells, there are enough signals to suggest a cautious approach to earnings.

Abbott Names Robert B. Ford President, Chief Operating Officer

Abbott Names Robert B. Ford President, Chief Operating Officer

- Mr. Ford, a 22-year Abbott veteran, is currently executive vice president of Medical Devices, Abbott's largest business

Brace for Impact: Cramer's 'Mad Money' Recap (Friday 10/12/18)

Brace for Impact: Cramer's 'Mad Money' Recap (Friday 10/12/18)

This earnings season could be full of surprises. Jim Cramer has your game plan for next week.

Weekly Roundup

Markets had one of the most volatile weeks in recent memory.

Our Game Plan for This Tumultuous Market

Let's review the portfolio and where we see opportunities in the market.

Adding to Palo Alto Networks

We are picking at a small amount of PANW as we look to reallocate the cash we raised through our exit of NUE.

Jim's Daily Rundown

Jim discusses Monday's market action, interest rates, oil, the cloud and a number of stocks.

Weekly Roundup

It was a volatile week on Wall Street.

Adding to Kohl's on Weakness

We believe today's down day has put the shares at an attractive level.

Jim's Daily Rundown

Jim discusses the ADP reading, how retail stocks have reacted to Amazon's wage hike, and much more.

Jim Cramer: Know Which Way the Wind Blows Before You Pick Stocks

Jim Cramer: Know Which Way the Wind Blows Before You Pick Stocks

PepsiCo, GE and just like the weather, the stock market is subject to change.

Last Week's Portfolio Changes

We downgraded one position and raised our price target on another last week.

Abbott′s FreeStyle® Libre 2, With Optional Real-Time Alarms, Secures CE Mark For Use In Europe

Abbott′s FreeStyle® Libre 2, With Optional Real-Time Alarms, Secures CE Mark For Use In Europe

- New features further enhance Abbott′s market leading sensor-based continuous glucose monitoring technology

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Straying from these names could land you in quicksand as the 4th quarter begins.

Weekly Roundup

The markets had a bumpy week to close out the third quarter.

Abbott Receives CE Mark For First Troponin Test To Help Predict The Chance Of Heart Attack In Apparently Healthy Adults Potentially Months To Years In Advance

Abbott Receives CE Mark For First Troponin Test To Help Predict The Chance Of Heart Attack In Apparently Healthy Adults Potentially Months To Years In Advance

- Research shows adding Abbott's High Sensitive Troponin-I diagnostic test to doctors' existing standard of care can help more accurately determine a person's chances of a heart attack or other cardiac event potentially months to years in advance

One-Year Results From Real-World Study Showed Abbott's Portico™ Transcatheter Aortic Valve Safely And Successfully Reduced Severe Aortic Stenosis

One-Year Results From Real-World Study Showed Abbott's Portico™ Transcatheter Aortic Valve Safely And Successfully Reduced Severe Aortic Stenosis

- Late-breaking data from real-world experience with the first fully repositionable and retrievable valve were consistent with previous results, and support that Portico can be successfully used in various anatomies in a real-world setting

Abbott's COAPT Trial Is a Breakthrough

This upside surprise announcement is too good to be ignored, so we are raising our price target.

Landmark Study Shows Treatment With Abbott's MitraClip® Is Superior To Medical Therapy For Advanced Heart Failure Patients With Significant Secondary Mitral Regurgitation

Landmark Study Shows Treatment With Abbott's MitraClip® Is Superior To Medical Therapy For Advanced Heart Failure Patients With Significant Secondary Mitral Regurgitation

- The COAPT trial met both the primary safety and efficacy endpoints and all secondary endpoints, including reducing all-cause mortality through two years

Weekly Roundup

U.S. equity markets pushed to record highs this week despite increased trade tensions.

Abbott Hosts Conference Call For Third-Quarter Earnings

Abbott Hosts Conference Call For Third-Quarter Earnings

ABBOTT PARK, Ill., Sept.

TheStreet Quant Rating: B (Buy)